Stockreport

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination ScheduleQDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardle [Read more]